Latest news
AstraZeneca’s heart drug failure raises a brutal question: how much treatment is too much treatment?
AstraZeneca and Ionis’ eplontersen did not reduce cardiovascular death and recurrent cardiovascular events in the overall CARDIO-TTRansform population. With 57% of participants already receiving a transthyretin stabiliser and another 24% starting one during the study, the result raises a harder question than whether one drug failed: how should regulators and payers judge added benefit when…
Soft-Cheese Listeria Outbreak Shows Food Safety Is Patient Safety
World Cup Health Guidance Turns Football Into a Public-Health Test
Not All Eye Infections Are Equal: New Evidence Points to a Precision Medicine Approach
What happens when surgeons no longer need to be in the same country as their patients?
EMA backs first oral obesity GLP-1 as pills push treatment towards mass-market adoption
As GLP-1 use expands, healthcare systems are confronting a new challenge: balancing obesity treatment with rising concerns about eating disorders and patient safety.
GSK’s Nuvalent Deal Turns Lung Cancer Precision Into a $10.6 Billion Access Race
J&J’s Firefly Bio Deal Puts KRAS Back Into the Oncology Arms Race
Parkinson’s Research Takes Aim at Mitochondrial Failure
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.